Expression of genes for 5-FU-metabolizing enzymes and response to irinotecan plus 5-FU-leucovorin in colorectal cancer

Anticancer Research

Volumn 26, Issue 6 C, 2006, Pages 4653-4658

  Noda, Eiji ^a   Maeda, Kiyoshi ^a   Inoue, Toru ^a   Nishihara, Tamahiro ^a   Nishiguchi, Yukio ^a   Ohira, Masaichi ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 FU; Colorectal cancer; Irinotecan; Thymidylate synthase

Indexed keywords

FLUOROURACIL; IRINOTECAN; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; MALE; METASTASIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; GENE EXPRESSION; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OROTATE PHOSPHORIBOSYLTRANSFERASE; RNA, MESSENGER; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; URIDINE PHOSPHORYLASE;

EID: 33845962388     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Fujii R, Seshimo A and Kameoka S: Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol 8: 72-78, 2003.
2. Isshi K, Sakuyama T, Gen T, Nakamura Y, Kuroda T, Katuyama T and Maekawa Y: Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU. Int J Clin Oncol 7: 335-342, 2002.
3. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB and Danenberg PV: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327, 2000.
4. Saltz LB, Danenberg DK, Paty PB, Kelsen DP, Kemeny N, Salonga D, Park JM and Danenberg PV: High thymidylate synthase (TS) expression does not preclude activity of CPT-11 in colorectal cancer (CRC). Proc Am Soc Clin Oncol 17: 281a, 1998.
5. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
6. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047, 2000.
7. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237, 2004.
8. Fujishima H, Kikuchi I, Miyanaga O, Ueda A, Baba E, Mitsugi K, Harada M and Nakano S: Phase I study of CPT-11 and bolus 5-FU/1-leucovorin in patients with metastatic colorectal cancer. Int J Clin Oncol 9: 92-97, 2004.
9. Mishima H, Ishida H, Iwamoto S, Morimoto T, Kato T, Tsujinaka T and Furukawa H: Multi-center phase II study of irinotecan + 5-FU/1-LV (RPMI) chemotherapy for patients with metastatic colorectal cancer (OGSG0201). Proc Am Soc Clin Oncol 23: 295s, 2005.
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New Guidelines to Evaluate the Response to Treatment in Solid Tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. pp. 205-216, 2002.
11. Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester T R, Park JM, Johansson J, Skinner KA, Chandrasoma P, DeMeester SR, Bremner CG, Tsai PI and Danenberg PV: Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 4: 135-142, 2000.
12. Heid CA, Stevens J, Livak KJ and Williams PM: Real time quantitative PCR. Genome Res 6: 986-994, 1996.
13. Gibson UE, Heid CA and Williams PM: A novel method for real time quantitative RT-PCR. Genome Res 6: 995-1001, 1996.
14. Guichard S, Hennebelle I, Bugat R and Canal P: Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 55: 667-676, 1998.
15. Rustum YM and Cao S: New drugs in therapy of colorectal cancer: preclinical studies. Semin Oncol 26: 612-620, 1999.
16. Ichikawa W, Uetake H, Nihei Z, Matso K, Fujita H and Yamada Y: Topoisomerase I (Topo-I) expression correlates to thymidylate synthase (TS) expression in colorectal cancer (CRC). Proc Am Soc Clin Oncol 18: 246a, 1999.
17. Paradiso A, Xu J, Mangia A, Chiriatti A, Simone G, Zito A, Montemurro S, Giuliani F, Maiello E and Colucci G: Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. Int J Cancer 111: 252-258, 2004.
18. Cascinu S, Aschele C, Barni S, Debernardis D, Baldo C, Tunesi G, Catalano V, Staccioli MP, Brenna A, Muretto P and Catalane G: Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 5: 1996-1999, 1999.
19. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412, 1995.
20. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M and Danenberg PV: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229, 1997.
21. Leichman CG: Thymidylate synthase as a predictor of response. Oncology (Williston Park) 12: 43-47, 1998.
22. Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z, Sugihara K and Hirayama R: Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 9: 786-791, 2003.
23. Hisamitsu K, Tsujitani S, Yamaguchi K, Fukuda K, Konishi I and Kaibara N: Expression of dihydropyrimidine dehydrogenase in cancer cells but not in stromal cells predicts the efficacy of fluorouracil treatment in patients with gastric carcinoma. Anticancer Res 24: 2495-2502, 2004.
24. Toriumi F, Kubota T, Saikawa Y, Yoshida M, Otani Y, Watanabe M, Kumai K and Kitajima M: Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma. Anticancer Res 24: 2455-2464, 2004.
25. Inaba M, Mitsuhashi J, Sawada H, Miike N, Naoe Y, Daimon A, Koizumi K, Tsujimoto H and Fukushima M: Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res 87: 212-220, 1996.
26. Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, Sugihara K, Sasaki Y and Hirayama R: Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 89: 1486-1492, 2003.
27. Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, Wadler S, Lenz HJ, Groshen S, Leichman L and Danenberg PV: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with non-response to 5-fluorouracil. Clin Cancer Res 4: 2371-2376, 1998.